

FIG. 1





FIG. 2

FIG. 3

CGI-I – change in clinical impression




FIG. 4

PGI-C – change in patient's impression




FIG. 5

MRI-ASL – change in blood flow in the brain




FIG. 6A

MRI-ASL – change in blood flow in the putamen at 52 weeks




FIG. 6B

MRI-ASL – change in blood flow in the pallidum at 52 weeks




FIG. 6C

MRI-ASL – change in blood flow in the premotor cortex at 52 weeks




FIG. 7A


*MDS-UPDRS Part III – site rating**

FIG. 7B


*MDS-UPDRS Part III – central rating**

FIG. 8




FIG. 9




FIG. 10
MDS-UPDRS Part III






FIG. 11A

*MDS-UPDRS Part III - site rating**Total population (n=316)*

Pooled: -1.44 , 80% CI= $(-2.83, -0.06)$; **-25.0%**

Prasinezumab 1500 mg: -1.88 , 80% CI= $(-3.49, -0.27)$; **-33.8%**

Prasinezumab 4500 mg: -1.02 , 80% CI= $(-2.64, 0.61)$; **-18.2%**


FIG. 11B***MDS-UPDRS Part III - site rating******MAO-B inhibitor treated (n=115)***

Pooled: -2.66 , 80% CI= $(-4.87, -0.45)$; **-39.0%**

Prasinezumab 1500 mg: -4.85 , 80% CI= $(-7.33, -2.37)$; **-71.1%**

Prasinezumab 4500 mg: -0.28 , 80% CI= $(-2.82, 2.25)$; **-4.0%**


FIG. 11C

*MDS-UPDRS Part III - site rating**Diffuse malignant (n=59)*

Pooled: -7.86 , 80% CI= $(-12.9, -2.82)$; **-63.9%**,

Prasinezumab 1500 mg: -8.4 , 80% CI= $(-14.2, -2.59)$; **-68.3%**


Prasinezumab 4500 mg: -7.77 , 80% CI= $(-13.4, -2.14)$; **-63.2%**

FIG. 12A***MDS-UPDRS Part III - central rating******Total population (N=316)***

Pooled: -1.88 , 80% CI= $(-3.31, -0.45)$; -35.0%

Prasinezumab 1500 mg: -2.44 , 80% CI= $(-4.09, -0.78)$; -45.4%

Prasinezumab 4500 mg: -1.33 , 80% CI= $(-2.99, 0.34)$; -24.7%


FIG. 12B***MDS-UPDRS Part III - central rating******MAO-B inhibitor treated (n=115)***

Pooled: -3.16, 80% CI=(-5.50, -0.82); -52.1%

Prasinezumab 1500 mg: -4.49, 80% CI=(-7.08, -1.90); -74.1%

Prasinezumab 4500 mg: -1.05, 80% CI=(-3.97, 1.87); -17.3%


FIG. 12C

MDS-UPDRS Part III - central rating**Diffuse malignant (n=59)**

Pooled: -9.24, 80% CI=(-15.4, -3.07); -76.1%

Prasinezumab 1500 mg: -13.2, 80% CI=(-21.2, -5.17); -108.7%


Prasinezumab 4500 mg: -8.56, 80% CI=(-16.0, -1.10); -70.5%

FIG. 13A**PASADENA Digital Motor Score****Total population (n=316)**

Pooled: -0.030 , 80% CI= $(-0.050, -0.010)$; **-25.0%**

Prasinezumab 1500 mg: -0.040 , 80% CI= $(-0.063, -0.017)$; **-30.3%**

Prasinezumab 4500 mg: -0.029 , 80% CI= $(-0.052, -0.006)$; **-21.5%**


FIG. 13B**PASADENA Digital Motor Score****MAO-B inhibitor treated (n=115)**

Pooled: -0.032 , 80% CI= $(-0.062, -0.003)$; **-26.0%**

Prasinezumab 1500 mg: -0.039 , 80% CI= $(-0.072, -0.049)$; **-31.0%**

Prasinezumab 4500 mg: -0.026 , 80% CI= $(-0.060, 0.008)$; **-20.9%**

FIG. 13C

PASADENA Digital Motor Score**Diffuse malignant (n=59)**

Pooled: -0.055 , 80% CI= $(-0.105, -0.005)$; **-35.7%**

Prasinezumab 1500 mg: -0.039 , 80% CI= $(-0.094, 0.017)$; **-25.2%**

Prasinezumab 4500 mg: -0.071 , 80% CI= $(-0.126, -0.017)$; **-46.2%**